A target cell–bound PD-1 agonist — e.g., localized to pancreatic β cells of a type 1 diabetes patient — could replicate this mechanism to inhibit attacking autoreactive T cells. The gene discussed is PDCD1; the disease is type 1 diabetes mellitus.